Aligos Therapeutics, Inc. announced that it has expanded its ongoing collaboration agreement with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH).
[Aligos Therapeutics, Inc.]
7992332
{7992332:EEEEEEEE}
apa
50
1
170695
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
